Epigenetic and genetic inactivation of tumor suppressor miR ‐135a in non‐small‐cell lung cancer
Thoracic Cancer · 2023-04 · 14 (11) · 1012-1020
DOI: 10.1111/1759-7714.14838 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 04.03.2023. Verfasst von Jin Eun Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Despite therapeutic advances, lung cancer prognosis remains poor. Loss of heterozygosity (LOH) in the 3p21 region is well documented in lung cancer, but the specific causative genes have not been identified. Materials and Methods Here, we aimed to examine the clinical impact of miR‐135a , located in the 3p21 region, in lung cancer. miR‐135a expression was assessed using quantitative real‐time polymerase chain reaction. LOH was analyzed at microsatellite loci D3S1076 and D3S1478, and promoter methylation status was determined by pyrosequencing of resected samples of primary non‐small‐cell lung cancer (NSCLC). The regulation of telomerase reverse transcriptase (TERT) was evaluated in lung cancer cells H1299 by luciferase report assays after treatment with miR‐135a mimics. Results miR‐135a was significantly downregulated in squamous cell cancer (SCC) tumor tissues compared to normal tissues ( p = 0.001). Low miR‐135a expression was more frequent in patients with SCC ( p = 2.9 × 10 −4 ) and smokers ( p = 0.01). LOH and hypermethylation were detected in 27.8% (37/133) and 17.3% (23/133) of the tumors, respectively. Overall, 36.8% (49/133) of the NSCLC cases harbored either miR‐135a LOH or promoter hypermethylation. The frequencies of LOH and hypermethylation were significantly associated with SCCs ( p = 2 × 10 −4 ) and late‐stage ( p = 0.04), respectively. MiR‐135a inhibited the relative luciferase activity of psiCHECK2‐ TERT ‐3'UTR.
Conclusion
These results suggest that miR‐135a may act as a tumor suppressor to play an important role in lung cancer carcinogenesis, which will provide a new insight into the translational value of miR‐135a . Further large‐scale studies are required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, South Korea.
- Biostatistics, Medical Research Collaboration Center in Kyungpook National University Hospital and School of Medicine, Kyungpook National University, Daegu, South Korea.
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
- Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
- Department of Anatomy, School of Medicine, Kyungpook National University, Daegu, South Korea.
ORCID-Profile: Jin Eun Choi, Shin Yup Lee, Seung Soo Yoo, Jae Yong Park
Zitieren
APA
Choi, J. E., Jeon, H. S., Wee, H. J., Lee, J. Y., Lee, W. K., Lee, S. Y., Yoo, S. S., Choi, S. H., Kim, D. S., & Park, J. Y. (2023). Epigenetic and genetic inactivation of tumor suppressor miR ‐135a in non‐small‐cell lung cancer. Thoracic Cancer, 14(11), 1012-1020. https://doi.org/10.1111/1759-7714.14838
Vancouver
Choi JE, Jeon HS, Wee HJ, Lee JY, Lee WK, Lee SY, et al. Epigenetic and genetic inactivation of tumor suppressor miR ‐135a in non‐small‐cell lung cancer. Thoracic Cancer. 2023;14(11):1012-1020. doi:10.1111/1759-7714.14838
BibTeX
@article{Choi2023,
author = {Choi, Jin Eun and Jeon, Hyo Sung and Wee, Hyun Jung and Lee, Ji Yun and Lee, Won Kee and Lee, Shin Yup and Yoo, Seung Soo and Choi, Sun Ha and Kim, Dong Sun and Park, Jae Yong},
title = {Epigenetic and genetic inactivation of tumor suppressor miR ‐135a in non‐small‐cell lung cancer},
journal = {Thoracic Cancer},
year = {2023},
volume = {14},
number = {11},
pages = {1012--1020},
doi = {10.1111/1759-7714.14838}
}
EUVIMED